{"entity":{"id":"nct04752813","kind":"trial","name":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","aka":[],"tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by BPGbio, active and no longer recruiting.","summary":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) is a phase 2 interventional study registered as NCT04752813 by BPGbio, with 50 participants enrolled, started 2022-08-22 and due to reach its primary completion in 2026-08-25. Interventions recorded: BPM31510, Temozolomide (TMZ) and Radiation.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04752813","url":"https://clinicaltrials.gov/study/NCT04752813"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04752813","phase":"2","setting":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","sponsor":"BPGbio","enrolled":50,"outcomes":[]},"route":"/trials/nct04752813/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}